We have continued to evaluate patients at risk for the development of cutaneous toxicities associated with molecularly targeted therapies. These evaluations include baseline evaluations prior to initiation of treatment and follow-up visits to monitor and treat these skin toxicities. We previously have worked and continue to work with oncology colleagues a) to optimally design treatment protocols to evaluate for and treat cutaneous toxicities, and b) to inform the research community of potentially newly described skin toxicities and methods for management of these adverse effects to optimize continued antineoplastic treatment of oncology patients through multiple peer-reviewed publications and lectures intramurally and extramurally. This fiscal year, we published a finding of hidradenitis suppurativa-like skin lesions with gamma-secretase inhibitors used to treat patients with desmoid tumors, providing insights into the pathogenesis of hidradenitis suppurativa.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010940-11
Application #
9779749
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
O'Sullivan Coyne, Geraldine; Woodring, Therese S; Lee, Chyi-Chia R et al. (2018) Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of Gamma-Secretase. J Invest Dermatol 138:979-981
Pichard, Dominique C; Cardones, Adela R; Chu, Emily Y et al. (2016) Sorafenib-Induced Eruption Mimicking Erythema Multiforme. JAMA Dermatol 152:227-8
Brooks, Sara; Linehan, W Marston; Srinivasan, Ramaprasad et al. (2011) Successful laser treatment of vandetanib-associated cutaneous pigmentation. Arch Dermatol 147:364-5
Jain, Lokesh; Gardner, Erin R; Figg, William D et al. (2010) Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 30:52-6
Azad, Nilofer S; Aragon-Ching, Jeanny B; Kong, Heidi H (2009) Clin Cancer Res 15:7749
Azad, Nilofer S; Aragon-Ching, Jeanny B; Dahut, William L et al. (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 15:1411-6
Kong, Heidi H; Turner, Maria L (2009) Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol 61:360-1
Kong, Heidi H; Fine, Howard A; Stern, Jere B et al. (2009) Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol 145:923-5
Lacouture, Mario E; Wu, Shenhong; Robert, Caroline et al. (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001-11
Kong, Heidi H; Sibaud, Vincent; Chanco Turner, Maria L et al. (2008) Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 144:820-2